Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study-Reference-Cited by-同舟云学术

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Published:2022-07 Issue: Volume:77 Page:S4-S5
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Wedemeyer Heiner,Aleman Soo,Brunetto Maurizia,Blank Antje,Andreone Pietro,Bogomolov Pavel,Chulanov Vladimir,Mamonova Nina,Geyvandova Natalia,Viacheslav Morozov,Sagalova Olga,Stepanova Tatyana,Manuilov Dmitry,Suri Vithika,An Qi,Flaherty John F.,Osinusi Anu,zur Wiesch Julian Schulze,Cornberg Markus,Zeuzem Stefan,Lampertico Pietro

Publisher

Elsevier BV

Subject

Hepatology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The HBV/HDV screening and linkage to care in drug users: A therapeutic diagnostic pathway (PDTA);MISSION;2024-05

2. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents;World Journal of Hepatology;2024-03-27

3. Antiviral Therapy of Chronic Hepatitis D Virus Infection – Addendum to the S3 Guideline “Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection” of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS);Zeitschrift für Gastroenterologie;2023-12

4. Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS);Zeitschrift für Gastroenterologie;2023-12

5. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference;Journal of Hepatology;2023-11